Deputy Editor Philippa Harris talks to Lise Jamieson (Health Economics and Epidemiology Research Office, University of Witswatersrand, South Africa) and Gesine Mayer-Rath (Health Economics and Epidemiology Research Office and the University of Boston, USA) about cost-effectiveness of long-acting cabotegravir for PrEP in South Africa.
Read the full article:
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv